Navigation Links
Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
Date:8/24/2009

BASKING RIDGE, N.J., Aug. 24 /PRNewswire/ -- Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system. The study is a double-blind, randomized, placebo-controlled, single ascending dose study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of RB006 administered subcutaneously, with and without intravenously administered RB007, in healthy adult volunteers. REG1 is a two component system composed of RB006, a specific and direct inhibitor of Factor IXa, and RB007, the specific controlling agent that reverses RB006. To date, this will be the first known use of an aptamer in humans delivered by the subcutaneous route of administration. Recently, Regado successfully completed a phase 2a study of intravenously administered REG1 in stable coronary artery disease patients undergoing elective PCI.

This Phase 1 study will have three primary objectives. First, it will determine the pharmacokinetics, bioavailability and pharmacodynamics of subcutaneous administered RB006. Second, it will determine the safety and tolerability of subcutaneous administered RB006 and third, it will determine the impact of intravenous administered RB007 on the pharmacokinetics, bioavailability and pharmacodynamics in subjects who received subcutaneous administered RB006. The study will enroll a total of 32 subjects.

Dr. Steven L. Zelenkofske, Chief Medical Officer of Regado Biosciences stated, "This is an important milestone in expanding the possible applications of the REG1 system." David J. Mazzo, PhD., President and CEO of Regado Biosciences, added, "The introduction of subcutaneously administered REG1 promises to bring an unprecedented level of individual specific control and flexibility to the physician caring for patients in need of chronic anticoagulant therapy."

About Regado Biosciences, Inc.

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

More information can be found at http://www.regadobio.com


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences Expands Medical Advisory Board
2. Regado Biosciences Establishes Medical Advisory Board
3. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
4. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
7. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
8. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
9. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
10. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
11. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... National executive ... leader with extensive assay development and biomarker expertise, as VP of Scientific Affairs ... CRO specializing in bio-analytical assay development and sample testing services. The organization acts ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... discovery of antibody therapeutics from millions-diverse immune repertoires, announces launch of its new ... Diego, California. Dave Johnson, PhD, CEO of GigaGen, will present on Surge at ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... development reported today that it is launching two new additions of its award-winning ... demonstrating new capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June ...
(Date:6/19/2017)... ... 2017 , ... A colony of healthy honey bees is like a superorganism--individual ... and nectar containing nutrients necessary for growth and survival. Better nutrition gives the colony ... point to a decline in honey bee health. Sick and weakened bees diminish the ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):